SMARCA4 and non-small cell lung carcinoma: The last SMARCA4 mutation analysis highlighted that the differences in all-cause mortality remained significant between the adenocarcinoma NSCLC patients that were mutated (N = 21) vs. wild-type (N = 204) (HR: 2.06; p = 0.003) [33].